| Nomura Healthcare Fund | June 30, 2026 (Unaudited) |
| Number of shares | Value (US $) | ||
| Common Stocks — 98.36%♣ | |||
| Biotechnology — 45.50% | |||
| AbbVie | 125,000 | $ 31,455,000 | |
| Abivax ADR † | 30,000 | 3,997,800 | |
| ACADIA Pharmaceuticals † | 92,648 | 2,343,995 | |
| Akero Therapeutics =, † | 25,000 | 16,250 | |
| Alkermes † | 260,000 | 13,622,700 | |
| Allogene Therapeutics † | 146,779 | 305,300 | |
| Alnylam Pharmaceuticals † | 30,000 | 9,030,900 | |
| Altimmune † | 100,000 | 304,000 | |
| Amarin ADR † | 9,500 | 151,430 | |
| Amgen | 47,000 | 17,019,640 | |
| AnaptysBio † | 93,732 | 6,326,910 | |
| Arcus Biosciences † | 379,100 | 11,687,653 | |
| Biogen † | 28,000 | 6,049,680 | |
| BioMarin Pharmaceutical † | 100,000 | 5,722,000 | |
| BioNTech ADR † | 18,000 | 1,674,900 | |
| Cellectis ADR † | 226,875 | 680,625 | |
| Cogent Biosciences † | 230,000 | 8,901,000 | |
| Coherus Oncology † | 900,000 | 1,260,000 | |
| Compugen † | 1,020,000 | 2,182,800 | |
| Cytokinetics † | 15,000 | 1,277,850 | |
| First Tracks Biotherapeutics † | 93,732 | 1,885,888 | |
| Fortress Biotech † | 6,666 | 20,398 | |
| Galmed Pharmaceuticals † | 1,701 | 946 | |
| Gilead Sciences | 210,000 | 26,531,400 | |
| GRAIL † | 85,000 | 5,802,950 | |
| Halozyme Therapeutics † | 220,000 | 17,219,400 | |
| Immunovant † | 122,100 | 4,704,513 | |
| Incyte † | 80,000 | 9,068,800 | |
| InnoCare Pharma Class H 144A #, † | 17,000 | 25,771 | |
| Instil Bio † | 50,000 | 384,500 | |
| Intellia Therapeutics † | 20,000 | 338,400 | |
| Janux Therapeutics † | 76,601 | 1,176,591 | |
| Karyopharm Therapeutics † | 33,333 | 325,664 | |
| Life Strategy † | 30,000 | 27,672 | |
| MacroGenics † | 420,000 | 1,940,400 | |
| Madrigal Pharmaceuticals † | 7,000 | 3,758,650 | |
| Moderna † | 20,000 | 1,400,600 | |
| Monte Rosa Therapeutics † | 200,000 | 4,840,000 | |
| MoonLake Immunotherapeutics † | 110,000 | 2,141,700 | |
| Mustang Bio † | 160 | 112 | |
| Myriad Genetics † | 50,000 | 285,500 | |
| Number of shares | Value (US $) | ||
| Common Stocks♣ (continued) | |||
| Biotechnology (continued) | |||
| Neurocrine Biosciences † | 70,000 | $ 11,797,450 | |
| NextCure † | 12,500 | 20,000 | |
| Olema Pharmaceuticals † | 50,000 | 625,500 | |
| Oruka Therapeutics † | 190,000 | 18,082,300 | |
| Phio Pharmaceuticals † | 50,000 | 51,250 | |
| ProQR Therapeutics † | 620,000 | 1,153,200 | |
| Puma Biotechnology † | 61,255 | 496,778 | |
| Regeneron Pharmaceuticals | 47,000 | 29,306,380 | |
| REGENXBIO † | 149,000 | 1,785,020 | |
| Rigel Pharmaceuticals † | 160,000 | 6,259,200 | |
| Rocket Pharmaceuticals † | 58,000 | 198,360 | |
| Roivant Sciences † | 338,181 | 11,968,226 | |
| Sangamo Therapeutics † | 400,000 | 21,560 | |
| Sarepta Therapeutics † | 11,000 | 197,670 | |
| Sio Gene Therapies =, † | 64,171 | 0 | |
| Syndax Pharmaceuticals † | 180,000 | 3,934,800 | |
| Ultragenyx Pharmaceutical † | 70,000 | 2,337,300 | |
| uniQure † | 217,500 | 10,018,050 | |
| United Therapeutics † | 3,000 | 1,625,490 | |
| Vaxcyte † | 20,000 | 1,162,600 | |
| Vertex Pharmaceuticals † | 25,000 | 12,418,250 | |
| Viking Therapeutics † | 330,100 | 12,877,201 | |
| Vir Biotechnology † | 500,000 | 5,095,000 | |
| Viridian Therapeutics † | 29,370 | 539,527 | |
| Voyager Therapeutics † | 5,700 | 19,950 | |
| Xencor † | 200,000 | 3,220,000 | |
| 341,101,350 | |||
| Commercial & Residential Mortgage — 1.97% | |||
| Fannie Mae † | 1,300,000 | 8,463,000 | |
| Federal Home Loan Mortgage † | 1,050,000 | 6,279,000 | |
| 14,742,000 | |||
| Healthcare — 2.39% | |||
| Abbott Laboratories | 90,000 | 8,166,600 | |
| Medtronic | 125,000 | 9,778,750 | |
| 17,945,350 | |||
| Healthcare Equipment — 4.18% | |||
| Boston Scientific † | 250,000 | 10,670,000 | |
| Stryker | 30,500 | 9,602,620 | |
| Zimmer Biomet Holdings | 128,379 | 11,052,148 | |
| 31,324,768 | |||
| Number of shares | Value (US $) | ||
| Common Stocks♣ (continued) | |||
| Healthcare Services — 1.88% | |||
| CVS Health | 75,000 | $ 7,758,750 | |
| Quest Diagnostics | 30,000 | 6,358,500 | |
| 14,117,250 | |||
| Life Sciences Tools & Services — 2.11% | |||
| Illumina † | 90,000 | 15,824,700 | |
| 15,824,700 | |||
| Managed Healthcare — 7.13% | |||
| Elevance Health | 63,000 | 24,363,990 | |
| UnitedHealth Group | 70,000 | 29,094,100 | |
| 53,458,090 | |||
| Pharmaceuticals — 33.20% | |||
| Arvinas † | 180,000 | 1,495,800 | |
| AstraZeneca | 131,243 | 24,503,635 | |
| Atea Pharmaceuticals † | 70,000 | 325,500 | |
| Chugai Pharmaceutical | 450,000 | 20,786,942 | |
| Cosmo | 14,000 | 1,150,970 | |
| Eli Lilly & Co. | 26,000 | 31,185,180 | |
| Euroapi † | 8,695 | 13,263 | |
| Johnson & Johnson | 20,000 | 5,079,400 | |
| Landos Biopharma =, † | 14,718 | 36,942 | |
| Merck & Co. | 215,000 | 27,627,500 | |
| Nektar Therapeutics † | 17,092 | 1,193,192 | |
| Organon & Co. | 29,500 | 399,430 | |
| Perrigo | 230,000 | 2,389,700 | |
| Pfizer | 1,200,000 | 28,896,000 | |
| Roche Holding | 55,000 | 22,609,751 | |
| Sanofi | 120,000 | 10,260,437 | |
| Structure Therapeutics ADR † | 58,000 | 3,112,860 | |
| Tarsus Pharmaceuticals † | 100,000 | 6,294,000 | |
| Theravance Biopharma † | 208,783 | 3,549,311 | |
| UCB | 130,137 | 38,959,274 | |
| Viatris | 1,170,018 | 18,579,886 | |
| WaVe Life Sciences † | 81,955 | 476,158 | |
| 248,925,131 | |||
| Total Common Stocks (cost $491,578,874) | 737,438,639 | ||
| Number of shares | Value (US $) | ||
| Rights — 0.01%♣ | |||
| Biotechnology — 0.01% | |||
| Ambit Bioscience =, †, π | 76,500 | $ 0 | |
| Contra Surface Oncolog =, † | 350,000 | 26,950 | |
| Mirati Therapeutics =, † | 60,000 | 42,000 | |
| Total Rights (cost $0) | 68,950 | ||
| Short-Term Investments — 1.96% | |||
| Money Market Mutual Funds — 1.96% | |||
| BlackRock Liquidity FedFund – Institutional Shares (seven-day effective yield 3.54%) | 3,666,430 | 3,666,430 | |
| Fidelity Investments Money Market Government Portfolio – Class I (seven-day effective yield 3.53%) | 3,666,431 | 3,666,431 | |
| Goldman Sachs Financial Square Government Fund – Institutional Shares (seven-day effective yield 3.59%) | 3,666,431 | 3,666,431 | |
| Morgan Stanley Institutional Liquidity Funds Government Portfolio – Institutional Class (seven-day effective yield 3.56%) | 3,666,430 | 3,666,430 | |
| Total Short-Term Investments (cost $14,665,722) | 14,665,722 | ||
| Total Value of Securities—100.33% (cost $506,244,596) | 752,173,311 | ||
| Liabilities Net of Receivables and Other Assets—(0.33%) | (2,477,408) | ||
| Net Assets Applicable to 27,170,457 Shares Outstanding—100.00% | $749,695,903 | ||
| ♣ | Categorizations used for financial reporting purposes may differ from categorizations used for regulatory compliance and/or internal classification purposes. |
| † | Non-income producing security. |
| = | The value of this security was determined using significant unobservable inputs and is reported as a Level 3 security. |
| # | Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. At June 30, 2026, the aggregate value of Rule 144A securities was $25,771, which represents 0.00% of the Fund’s net assets. |
| π | Restricted security. These investments are in securities not registered under the Securities Act of 1933, as amended, and have certain restrictions on resale which may limit their liquidity. At June 30, 2026, the aggregate value of restricted securities was $0, which represented 0.00% of the Fund’s net assets. See table below for additional details on restricted securities. |
| Restricted Securities | ||||||
| Investments | Date of Acquisition | Cost | Value | |||
| Ambit Bioscience | 11/12/14 | $0 | $0 |
| Summary of abbreviations: |
| ADR – American Depositary Receipt |